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Abstract
Melatonin "the light of night" is secreted from the pineal gland principally at night. The hormone is
involved in sleep regulation, as well as in a number of other cyclical bodily activities and circadian
rhythm in humans. Melatonin is exclusively involved in signalling the 'time of day' and 'time of year'
(hence considered to help both clock and calendar functions) to all tissues and is thus considered
to be the body's chronological pacemaker or 'Zeitgeber'.
The last decades melatonin has been used as a therapeutic chemical in a large spectrum of diseases,
mainly in sleep disturbances and tumours and may play a role in the biologic regulation of mood,
affective disorders, cardiovascular system, reproduction and aging. There are few papers regarding
melatonin and its role in adolescent idiopathic scoliosis (AIS). Melatonin may play a role in the
pathogenesis of scoliosis (neuroendocrine hypothesis) but at present, the data available cannot
clearly support this hypothesis. Uncertainties and doubts still surround the role of melatonin in
human physiology and pathophysiology and future research is needed.
Background
Pharmacology
The biological pathway of melatonin is not simple. In the
biosynthesis of melatonin, or N-acetyl-5-methoxytryp-
tamine, tryptophan is first converted by tryptophan
hydroxylase to 5-hydroxytryptophan, which is decarboxy-
lated to serotonin (figure 1 and 2). The synthesis of mela-
tonin from serotonin is catalyzed by two enzymes
(arylalkylamine  N-acetyltransferase and hydroxyindole-
O-methyltransferase) (HIOMT) that are largely confined
to the pineal gland [1,2]. Melatonin is rapidly metabo-
lized, chiefly in the liver, by hydroxylation to 6-
hydroxymelatonin. The urinary excretion of 6-sulfa-
toxymelatonin (the chief metabolite of melatonin)
closely parallels serum melatonin concentrations [3].
Synthesis of melatonin-the role of light
In humans melatonin is produced mainly in the pineal
gland and a small portion in the retina. The synthesis and
release of melatonin are stimulated by darkness, mela-
tonin is the "chemical expression of darkness" and inhib-
ited by light [4]. Photic information from the retina is
transmitted to the pineal gland through the suprachias-
matic nucleus of the hypothalamus (SCN) and the sympa-
thetic nervous system [5]. During daylight hours the
retinal photoreceptor cells are hyperpolarized and inhibit
the release of norepinephrine [6]. With the onset of dark-
ness the photoreceptors release norepinephrine, thereby
activating the system, and a number of a1- and b1-adren-
ergic receptors in the gland increases [7]. The activity of
arylalkylamine N-acetyltransferase, the enzyme that regu-
lates the rate of melatonin synthesis, is increased, initiat-
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Biosynthesis of melatonin Figure 1
Biosynthesis of melatonin. Modified from [48].Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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ing the synthesis and release of melatonin. As the
synthesis of melatonin increases, the hormone enters the
bloodstream through passive diffusion.
Environmental lighting does not cause the rhythm but
entrains it (alters its timing) [5]. Light has two effects on
melatonin: day-night light cycles modify the rhythm of its
secretion, and brief pulses of light of sufficient intensity
and duration abruptly suppress its production [8]. In nor-
mal subjects, exposure to light inhibits melatonin secre-
tion in a dose-dependent manner. The threshold is 200 to
400 lux (equivalent to ordinary fluorescent light), and
maximal inhibition occurs after exposure to intense light
(600 lux or higher) for one hour [9].
Levels of melatonin
In humans melatonin has diurnal variations. The hor-
mone secretion increases soon after the onset of darkness,
peaks in the middle of the night, between 2 and 4 a.m.,
and gradually falls during the second half of the night (fig-
ure 3). This circadian rhythm of secretion plays an impor-
tant role in its hormonal activity. In some
endocrinopathies like Cushing disease this circadian
rhythm of secretion of the hormone is absent. Several dis-
eases such as: Klinefelter's syndrome, Turners syndrome,
psoriasis vulgaris, myelomenigocoele, and sarcoidosis
have been associated with disrupted melatonin profiles,
both in terms of rhythm and magnitude [10].
Seasonal variations
There is a seasonal variation in human melatonin, with an
earlier phase in summer and increased levels and duration
of secretion in winter in high geographical latitudes [4].
Age variations
Serum melatonin concentrations vary considerably
according to age. Infants younger than three months of
age secrete very little melatonin. Melatonin secretion
increases and becomes circadian in older infants, and the
peak nocturnal concentrations are highest (average, 325
pg per milliliter [1400 pmol per liter]) at the age of one to
three years, after which they decline gradually 10–15%
per decade [11] (figure 4). In normal young adults, the
average daytime and peak night time values are 10 and 60
pg per millilitre (40 and 260 pmol per liter), respectively
[3].
The bioavailability of melatonin-sides effects
The bioavailability of orally administered melatonin var-
ies widely. Oral doses (1 to 5 mg), which are now widely
available in drugstores and food stores, result in serum
melatonin concentrations that are 10 to 100 times higher
than the usual night time peak within one hour after
ingestion, followed by a decline to base-line values in four
to eight hours. Very low oral doses (0.1 to 0.3 mg) given
in the daytime result in peak serum concentrations that
are within the normal night time range [12].
Melatonin is available in drugstores in tablets (0.2 mg, 0.3
mg, 0.5 mg, 1 mg, 2.5 mg, 3 mg, 5 mg), timed release tab-
lets (1 mg, 2 mg, 3 mg) and liquid (1 mg/mL, 1 mg/4 ml).
No serious side effects or risks (e.g., hypothermia,
increased sleepiness, decreased alertness, and possibly
reproductive effects) have been reported in association
with the ingestion of melatonin. The dose-dependent
physiologic effects of the hormone, however have not yet
been properly evaluated in people who take large doses
for prolonged periods of time. Despite the general
absence of a marked endocrine action, decreased serum
luteinizing-hormone concentrations and increased serum
prolactin concentrations have been reported after the
administration of pharmacologic doses of melatonin in
normal subjects [13,14].
Receptors of melatonin
The amphibian melatonin receptor was cloned in 1994,
and cloning of the sheep and human receptors was
reported shortly thereafter with high structural similarity
(80%) between sheep and human clones [15,16]. Two
membrane-bound melatonin-binding sites belonging to
distinct groups have been identified: ML1 (high-affinity)
and ML2 (low-affinity) receptors [17,18].
Melatonin receptors have been located in the suprachias-
matic nucleus, the pars tuberalis, and in the cerebellum
[19,20]. Although the human cerebellum is not consid-
ered as an endocrine system, the external zone of the cer-
ebellar molecular layer has the highest density of
melatonin receptors: a convergency site for stimulatory
Melatonin molecule Figure 2
Melatonin molecule. (Modified from [86]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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and inhibitory afferents to the Purkinje cells. The Purkinje
cells are the only output from the cerebellar cortex and are
inhibitory for vestibular, oculomotor, and cerebellar neu-
rons [19,21].
Activation of ML1 melatonin receptors, which belong to
the family of guanosine triphosphate-binding proteins, a
family that includes the serotonin and b-adrenergic recep-
tors, results in the inhibition of adenylate cyclase activity
in target cells [22,23]. ML1 receptors are of clear impor-
tance to the nervous system. The greatest density of high-
affinity melatonin receptors (ML1) in humans are located
in the suprachiasmatic nucleus of the hypothalamus
(SCN). These receptors are responsible for chronobiologi-
cal effects at the SCN, the circadian pacemaker. Within
SCN, melatonin reduces neuronal activity in a time -
dependant manner.
With the use of the polymerase chain reaction (PCR), two
subtypes of a high-affinity melatonin receptor (ML1),
were cloned from several mammals, including humans:
the Mel1a and Mel1b receptors, which are now referred to
as the MT1 and MT2 receptors, respectively [15,24]. This
opens large new perspectives and approaches not only for
the study of the mechanism of action of melatonin but
also for the development of new molecules for therapeutic
use. Several major actions of melatonin are mediated by
the membrane receptors MT1 and MT2. They belong to
the superfamily of G-protein coupled receptors contain-
ing the typical seven transmembrane domains. MT1
receptors activate protein kinase C-b, whereas MT2 recep-
tors inhibit the soluble guanylate cyclase pathway while
stimulating protein kinase C. MT1 receptors have the
most widespread distribution in the rodent brain, account
for the majority of melatonin-binding sites in most target
tissues, and are widely believed to account for many mela-
tonin actions in the brain. The MT2 receptor does not
appear to be necessary for photoperiodic responses in
hamsters [24]. These receptors are members of a new
receptor group that is distinct from other G-protein-linked
groups. The effects of melatonin on SCN activity are medi-
ated by at least two different receptors. They are insensi-
tive during the day, but sensitive at dusk and dawn. MT2
causes phase shifts and during early night period MT1
decrease neuronal firing rate and amplitude [25] (figure 5,
Diurnal variations of melatonin levels Figure 3
Diurnal variations of melatonin levels. The hormone secretion increases soon after the onset of darkness, peaks in the middle 
of the night, between 2 and 4 a.m., and gradually falls during the second half of the night. (Modified from [87]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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6, 7).
The ML2 receptors are coupled to the stimulation of phos-
phoinositide hydrolysis, are a distinct molecular species,
but their distribution has not been determined. The ML2
(also named MT3) receptor was poorly characterized and
enigmatic until a recent study identified it as a form of
quinone reductase. This enzyme is widely distributed in
different tissues and across different species. The impor-
tance of melatonin binding to this enzyme is unclear. Spe-
cific melatonin agonists are becoming available, which
lack binding to the MT3/quinone reductase receptor;
these agents will help to isolate the specific effects medi-
ated by the high-affinity melatonin receptors, and may
become important options for pharmacologic treatment
of insomnia without the potential for side effects from
interactions with the MT3/quinone reductase binding site
[23].
Melatonin may also act at intracellular sites. Through
binding to calmodulin (figure 8) the hormone may
directly affect calcium signalling by interacting with target
enzymes such as adenylate cyclase and phosphodieste-
rase, as well as with structural proteins [26]. There are
melatonin receptors in various regions of the human
brain and in the gut, ovaries and blood vessels [27-29].
Non-neural melatonin receptors (such as those located in
the pars tuberalis of the pituitary) probably regulate
reproductive function, especially in seasonally breeding
species. Receptors located in peripheral tissues (e.g., arter-
ies) may be involved in the regulation of cardiovascular
function and body temperature. MT1 seems to mediate
mainly vasoconstriction, whereas MT2 mainly causes
vasodilation.
Moreau at al [30] investigated the melatonin signal trans-
duction pathway and demonstrated that melatonin sig-
nalling is clearly impaired in osteoblasts of all patients
with idiopathic scoliosis.
Role of melatonin in human biology
Circadian rhythm, jet lag and night shift
In humans the circadian rhythm for the release of mela-
tonin from the pineal gland is closely synchronized with
Age variations of melatonin levels Figure 4
Age variations of melatonin levels. The hormone secretion increases in early childhood. In adolescent there is a decrease of the 
hormone concentration. The levels continued to decline gradually during middle age. In old population the levels of melatonin 
in serum are very low. (Modified from [88]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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the habitual hours of sleep. Alterations in synchroniza-
tion due to phase shifts (resulting from airline flights
across time zones or unusual working hours) are corre-
lated with sleep disturbances.
A phase shift in endogenous melatonin secretion occurs
in airplane passengers after flights across time zones [31],
in night-shift workers [32], and in patients with the
delayed-sleep-phase syndrome (delayed onset of sleep
and late waking up) [33].
The ingestion of melatonin may alter the normal circa-
dian rhythm of melatonin secretion, but the reports on
this effect are inconsistent, probably because of variations
in the timing of the administration of melatonin in rela-
tion to the light-dark cycle [5]. The administration of
melatonin in the early evening results in an earlier
increase in endogenous night time secretion [34]. Exoge-
nous melatonin appears to have some beneficial effects
on the symptoms of jet lag, although the optimal dose
and timing of ingestion have yet to be determined [5].
Sleep disturbances
Serum melatonin concentrations were found to be signif-
icantly lower, with later peak night time concentrations,
in elderly subjects with insomnia than in age-matched
controls without insomnia [35].
Ingestion of melatonin affects sleep propensity (the speed
of falling asleep), as well as the duration and quality of
sleep, and has hypnotic effects. Oral administration of five
mg of melatonin caused a significant increase in sleep pro-
pensity and the duration of rapid-eye-movement (REM)
sleep [36,37]. In other studies, sleep propensity was
increased in normal subjects given much lower doses of
melatonin (0.1, 0.3, or 1 mg), and sleepiness in the morn-
ing was not increased [12]. The time to the maximal hyp-
notic effect varies linearly from about three hours at noon
to one hour at nine p.m. [38]. The administration of mela-
tonin for three weeks in the form of sustained-release tab-
lets (1 mg or 2 mg per day) may improve the quality and
duration of sleep in elderly persons with insomnia [39].
The hypnotic effect of melatonin may thus be independ-
ent of its synchronizing influence on the circadian rhythm
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN) Figure 5
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN). The effects of melatonin on SCN activity 
are mediated by at least two different receptors. They are insensitive during the day, but sensitive at dusk and dawn. MT2 
causes phase shifts and during early night period MT1 decrease neuronal firing rate and amplitude. (Modified from [89]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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and may be mediated by a lowering of the core body tem-
perature [40].
Ophthalmic exams show that elevated intraocular pres-
sure and large cup-to-disk ratios (index of optic nerve
damage in patients with glaucoma) are independently
associated with earlier melatonin timing (early phase).
Lower illumination exposure also has independent asso-
ciations with earlier melatonin timing. Conceivably, oph-
thalmic and illumination factors might have an additive
effect on the timing of melatonin excretion, which in turn
might predispose individuals to experience early morning
awakenings. It is evident that daily illumination, ophthal-
mic factors, sleep duration, and race each have independ-
ent associations with melatonin. The observation that
Blacks have lower illumination exposure, greater ophthal-
mic dysfunction, and higher 6-sulfatoxymelatonin levels
merits further empirical study [41].
Affective disorders
Although humans are no photoperiodic, bright light is
essential for the suppression of melatonin and the phase
shift of the circadian rhythm [42]. Low night time serum
melatonin concentrations have been reported in patients
with depression [43] and patients with seasonal affective
disorder have phase-delayed melatonin secretion [44].
Although bright-light therapy (BLT) reduced the depres-
sion scores of such patients in one study, a direct associa-
tion with the phase-shifting effect of light on melatonin
secretion was not substantiated [42].
Sexual maturation
Abnormally high or pharmacologic concentrations of
melatonin in women are associated with altered ovarian
function and anovulation. It is believed that the hormone
also has antigonadal or antiovulatory effects in humans,
as it does in some seasonal and nonseasonal mammalian
breeders. Melatonin acts in gonades indirectly, reducing
the secretion of gonadotropines and mainly LH [45]. The
menarche is related with episodic secretion of LH during
the night [46,47]. Melatonin may play a role in the timing
of puberty and the onset of puberty in humans may be
related to the decline in melatonin secretion that occurs as
children grow [5].
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN) Figure 6
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN). At the beginning of the night melatonin 
causes a phase advance (dashed line) and in the early morning hours causes a phase delay (dotted line)-MT2 receptors. (Modi-
fied from [89]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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The age at menarche in healthy population regressed by
northern latitude showed that there is a statistical signifi-
cant correlation (p < 0,001). For lower latitudes (as for
example in Australia) there are no, at least recent, data
available for the prevalence of scoliosis. Late age at
menarche is noted in northern geographic latitudes and in
Inuits (Eskimos) and the age of menarche decreases as the
latitude is approaching the 30°-25° then it increases
again [48,49]. The amount of sunlight and the quality of
light may play a major role for the different initiation of
menses in above-mentioned latitudes. Probably the
increased levels of melatonin in countries with poor light
environmental conditions as in northern countries
reduced the secretion of LH and causes delayed age at
menarche. The elevated levels of melatonin may also
explains the inhibition of ovulation in the Inuits (Eski-
mos) during the months of winter night period [48,49].
Aging
The decrease in night time serum melatonin concentra-
tions that occurs with aging, together with its multiple
biologic effects, has led several investigators to suggest
that melatonin has a role in aging and age-related diseases
[50,51]. Studies in rats and mice suggest that diminished
melatonin secretion may be associated with an accelera-
tion of the aging process [52]. It is interesting to note that
the majority of herbs used in traditional Chinese medi-
cine for retarding age-related changes and for treating dis-
eases associated with the generation of free radicals also
contain the highest levels of melatonin [53]. However, the
age-related reduction in night time melatonin secretion
could well be a consequence of the aging process rather
than its cause, and there are no data supporting an antiag-
ing effect of melatonin in humans.
Malignancy
There is evidence from experimental studies that mela-
tonin influences the growth of spontaneous and induced
tumours in animals. Pinealectomy enhances tumour
growth, and the administration of melatonin reverses this
effect or inhibits oncogenesis caused by carcinogens [54].
Melatonin in combination with interleukin 2 has been
used in clinical trials in patients with malignant tumours
[55]. Data on the relation between melatonin and onco-
genesis in humans are conflicting, but the majority of the
reports point toward protective action. Low serum mela-
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN) Figure 7
Effects of exogenous melatonin on nucleus suprachiasmatic neuronal activity (SCN). Melatonin administered during the early 
night period may resynchronize SCN neurons and thereby reinforce amplitude of SCN output signal without an effect on cir-
cadian phase-MT1 receptors. (Modified from [89]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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tonin concentrations and low urinary excretion of mela-
tonin metabolites have been reported in women with
estrogens-receptor-positive breast cancer and men with
prostatic cancer [56-58]. The mechanism by which mela-
tonin may inhibit tumour growth is not known.
Cardiovascular system
The evidence obtained during the last years suggests that
melatonin exerts certain effects upon the cardiovascular
system. The presence of vascular melatoninergic receptors
binding sites has been demonstrated. It has been shown
that patients with coronary heart disease have a low mela-
tonin production rate, especially those with higher risk of
cardiac infarction and/or of sudden death. There are clin-
ical data, reporting alterations of melatonin concentra-
tions in serum in coronary heart disease. People with high
levels of low-density lipoprotein (LDL)-cholesterol have
low levels of melatonin. It has been shown that melatonin
suppresses the formation of cholesterol, reduces LDL
accumulation in serum and modifies fatty acid composi-
tion of rat plasma and liver lipids. People with hyperten-
sion demonstrate lower melatonin levels versus those
with normal blood pressure. It is questionable whether
the administration of the hormone will decline blood
pressure to normal range [59].
Bone protector
Melatonin may have a direct effect on bone. Suppression
of melatonin secretion lowered serum calcium concentra-
tion, an effect prevented by melatonin administration.
Treatment of ovariectomized rats with melatonin prevents
bone loss by an effect partly dependent on residual estra-
diol levels. Melatonin presumably acts as an autacoid in
bone cells since it is present in high quantities in bone
marrow, where bone cell precursors are located. Mela-
tonin dose-dependently augments proteins that are incor-
porated into the bone matrix, like procollagen type I c-
peptide. Osteoprotegerin, an osteoblastic protein that
inhibits the differentiation of osteoclasts is also aug-
mented by melatonin in vitro. Melatonin through its free
radical scavenger and antioxidant properties may impair
osteoclast activity [60].
Interaction with Calmodulin
Many investigators have noted abnormalities in the struc-
ture and the function of thrombocytes in patients with idi-
opathic scoliosis. Those with larger scoliotic curves have a
higher concentration of a more dense type of platelet,
compared with those with small curves or control subjects
[61]. Calmodulin is a calcium-binding receptor protein,
and it regulates the contractile properties of muscles and
platelets. Increased calmodulin levels in platelets have
been shown to be associated with the worsening of AIS.
Through binding to calmodulin, melatonin may directly affect calcium signalling Figure 8
Through binding to calmodulin, melatonin may directly affect calcium signalling.(Modified from [90]).Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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Melatonin binds to calmodulin and has been shown to
act as a calmodulin antagonist. The relationship seems to
be complex. Nikaido, et al [62] showed that several cal-
modulin antagonists inhibited nocturnal melatonin syn-
thesis in chick pineal cells. Their results supported the
hypothesis that melatonin acts as a calmodulin antagonist
and that cellular functions may be rhythmically regulated
by melatonin modulation of calmodulin dependent pro-
tein phosphorylation. Benitez-King et al [63] detected cal-
modulin immunoreactivity in ependymocytes in the
follicular zone and in interstitial cells in the perifollicular
zone in the chicken pineal. The lack of calmodulin immu-
noreactivity in pinealocytes raised questions about its pro-
posed function in melatonin synthesis. Hazlerigg et al
1996 [64] supported the hypothesis that under physiolog-
ical conditions, melatonin synchronizes different body
rhythms through cytoskeletal rearrangements mediated
by its calmodulin antagonism.
Melatonin and adolescent idiopathic scoliosis
The cause of adolescent idiopathic scoliosis (AIS) in
humans remains obscure and probably multifactorial. Át
present there is no proven method or test available to
identify children or adolescent at risk of developing AIS or
identify which of the affected individuals are at risk of pro-
gression. Reported associations are linked in pathogenesis
rather than etiologic factors. A number of suggestions con-
cerning its aetiology have been proposed including neu-
romuscular, connective tissue structure, vestibular
dysfunction, melatonin secretion, platelet microstructure,
mechanical, growth related and developmental, asymme-
try in the brainstem, genetic factor, equilibrium dysfunc-
tion and impairment of proprioception leading to the
idea that a disturbance of postural control but no single
factor has been identified so far. Many authors think that
a relation exists between the origin of scoliosis and bal-
ance troubles. Visual impairment has been shown to
increase the prevalence of idiopathic scoliosis in human
subjects when compared to the prevalence of the general
population [65-70]. Research is needed to better define
the role of all factors in AIS development.
Melatonin may play a role in the pathogenesis of scoliosis
(neuroendocrine hypothesis) but at present, the data
available cannot clearly show the role of melatonin in
producing scoliosis in humans.
Machida et al found that pinealized chickens developed
scoliosis and attributed this effect to decreased melatonin
production. They show that scoliosis could be prevented
by administration of melatonin. [71,72]. In another study
they found significantly decreased levels of melatonin
(actual serum levels with multiple regular overnight sam-
ples) in five adolescents with progressive curves, while
those with stable curves were similar to controls [73].
They postulate that melatonin bonded calmodulin,
thereby affecting calcium metabolism with muscle cells
and thereby causing asymmetry in paraspinal muscle
growth and development. The findings in pinealect-
omised chickens introduced the 'melatonin-deficiency
hypothesis' as a possible cause of human AIS. Later Hili-
brand et al [74] using morning and evening urine samples
assayed for melatonin were unable to confirm differences
between adolescent females with idiopathic scoliosis and
controls. Contrary to their hypothesis, the urinary mela-
tonin was actually slightly higher in the scoliosis patients
than in the controls. The four patients in their study who
subsequently had progressive curves did have lower val-
ues than the patients with stable curves or the controls,
however the difference was not statistically significant (p
< 0.25). Bagnall et al [75] also measured melatonin levels
in adolescents with idiopathic scoliosis. In a small group
(7 patients, 7 controls) of older patients with scoliosis, he
was unable to show statistically significant differences in
melatonin levels with 2 am and 2 pm serum samples. The
authors remarked that their patients were 2–3 years
beyond their point of maximum progression of curvature
and that studies of adolescents during the maximal
growth phase would be important. They suggested that
melatonin's activity may be through the intermediation of
growth hormone. Fagan et al [76] measured the 24 hour
urinary melatonin production in patients with AIS. No
significant difference in diurnal, nocturnal or total urine
6-sulphatoxy melatonin excretion was found between
adolescent patients with a stable spinal deformity (AIS) or
severe deformity requiring surgery and controls of similar
age and gender. The author suggests that absolute levels of
melatonin in an individual are less likely to be important
than the rhythm of secretion. Brodner et al[77] measured
the levels of serum melatonin and the excretion of urinary
6-hydroxy-melatonin-sulphate, the principal metabolite
of melatonin in nine patients with adolescent idiopathic
scoliosis and in ten age-and gender-matched controls.
There were no statistically significant differences in the
secretion of serum melatonin or the excretion of urinary
6-hydroxy-melatonin-sulphate between the patients and
the control group. Cheung et al [78] reports that none of
the 18 pinealectomised monkeys developed scoliosis in a
mean follow up period of 28 months, and it strongly sug-
gests that the possible etiologic factors producing idio-
pathic scoliosis in lower animals are different from
primates, and that findings in lower animals cannot nec-
essarily be extrapolated to human beings. Using the indi-
rect way by examining the metabolite of melatonin, the
urinary 6-sulfatoxyl-melatonin, as well as the pineal gland
metabolism, where the melatonin is produced, by the
assessment of the glucose metabolism using F-18 FDG
brain PET(F-18 fluorodeoxyglucose (FDG) brain positron
emission tomography (PET)) it was shown that there was
no significant difference in melatonin secretion and noScoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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melatonin deficiency between the patients with AIS and
the control group [79].
Thus the data regarding human melatonin levels is mixed
at best and the melatonin deficiency as a causative factor
in the aetiology of scoliosis cannot be supported. The bio-
logical relevance of melatonin in AIS is controversial
because: a) no significant decrease in circulating mela-
tonin level has been observed in a majority of studies, b)
experimental pinealectomy did not lead systematically to
a scoliosis in all pinealectomised chicken, c) melatonin
injections in pinealectomised animals did not always pre-
vent the formation of scoliosis.
There are good physiologic reasons why the chicken
model cannot be simply extrapolated to the human situa-
tion. The distribution of melatonin receptors in the
chicken is more widespread than in other species. They are
found throughout the brainstem and in the dorsal grey
matter of the signal cord, particularly in the lumbar
region. Receptors have even been demonstrated in the
chicken ovary and testicle. In humans no extrapineal
source of melatonin production has been shown to affect
the circadian rhythm of hormone levels. In humans pine-
alectomy leads to a loss of the night time melatonin peak
and a drop in basal levels below detection, whereas in
chickens, it only eliminates the night time peak. Although
melatonin serves as the zeitgeber for many animals, its
actions appear to differ between humans, other mam-
mals, and other vertebrates [74,76]. Moreover idiopathic
scoliosis patients do not have documented immune defi-
ciency or difficulties with sleep, two deficiencies, which
might be expected if melatonin was decreased. Looking at
the accessible to us peer review literature there was no
report of any sleep disturbances in children with AIS.
Children who were operated for scoliosis don't show
increase incidence of postoperative infections compare
with the incidence of other operations in the same age
group of people, something that someone would expect if
these children have immunodeficiency due to lower levels
of melatonin. Murphy et al [80] studied children who
were hospitalized for the management of idiopathic scol-
iosis (IS) and neuromuscular scoliosis (NMS) via analysis
of the 2000 Healthcare Cost and Utilization Project Kid
Inpatient Database. Children with NMS more frequently
developed pneumonia (3.5% vs. 0.7%, p < 0.001), respi-
ratory failure (24.1% vs. 9.2%, p < 0.001), urinary tract
infections (5.3% vs. 0.7%, p < 0.001), and surgical wound
infections (1.3% vs. 0.3%, p < 0.001). Coe et al [81] in a
retrospective study used Scoliosis Research Society (SRS)
morbidity and mortality data submitted for surgical cases
operated from 2003 to 2005 to determine whether scolio-
sis subtype (degenerative vs. idiopathic) is an independ-
ent predictor of complications and mortality in surgery for
adult scoliosis by an analysis of the SRS database of com-
plications as submitted by its members. The study demon-
strated that the complication rate for surgery for
degenerative scoliosis is significantly higher than idio-
pathic scoliosis (15,6% vs. 12,3% respectively). The differ-
ence was statistically significant (p < 0.01). In another
study of 2876 patients who were treated surgically for spi-
nal deformity the infection rate was 2,4%, while degener-
ative scoliosis had an infection rate of 6,2%,
neuromuscular scoliosis had 3,6%, adult idiopathic scol-
iosis had 1,6%, while adolescent idiopathic scoliosis
(AIS) had an infection rate of only 0,9% [82].
Another implication for the melatonin deficiency hypoth-
esis is that increase incidence of scoliosis has not been
observed in children after pinealectomy or pineal irradia-
tion because of pineal neoplasias, although they have luck
of serum melatonin [83,84]. Murata et al [84] analyzed
secretion of melatonin and pituitary hormones in 14
patients with germinoma originating in the pineal or the
hypothalamic-neurohypophyseal region. Germinoma
cells originating from the pineal gland impair the produc-
tion of melatonin by pineocytes and consequently induce
a permanent melatonin deficiency in those patients, but
these patients don't developed idiopathic scoliosis.
Moreau et al [30] performed in vitro assays with bone-
forming cells isolated from 41 patients with AIS and 17
control patients exhibiting another type of scoliosis or
non. Primary osteoblast cultures prepared from bone
specimens obtained intraoperatively during spine surger-
ies were used to test the ability of melatonin and
Gpp(NH)p, a GTP analogue, to block cAMP accumulation
induced by forskolin. In parallel, melatonin receptor and
Gi protein functions were evaluated. They found dysfunc-
tion in osteoblasts isolated from 100% of the patients
with AIS tested. Classification of patients with AIS into 3
distinct groups suggested the presence of different muta-
tions that could cause such dysfunction. Among possible
causes, the authors suggest that abnormalities in Gi pro-
teins function could be involved in AIS pathogenesis
The prevalence of scoliosis differs at different countries. In
Northern latitude the prevalence is high compared with
this towards 25–30° (Finland 9,2% -Greece 2,9%). The
age at menarche regressed by latitude showed that there is
a statistical significant correlation. The regression curves
of prevalence of adolescent idiopathic scoliosis by latitude
and age at menarche by latitude are of similar pattern
[48].
The prevalence of scoliosis in a population of blind
women was 42,3% while the prevalence in the general
population in the same region is 2,9%. Melatonin may
play a role in the pathogenesis of scoliosis [85]. It could
be hypothesized that the levels of melatonin in this pop-Scoliosis 2007, 2:6 http://www.scoliosisjournal.com/content/2/1/6
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ulation (women in northern latitude, and blind women)
causes delay sexual maturation and render the growing
immature spine of these women to longer exposure, until
maturity, to detrimental causative factors of scoliosis [85].
Conclusion
Melatonin the "light of night" is not a simple hormone. It
has many complex functions, which are only recently
being defined. In comparison with other signalling mole-
cules the numerous actions that have been attributed to
melatonin are exceptional. Unfortunately there are differ-
ences in the pharmacology of melatonin between the spe-
cies and different biological circadian rhythms. Chicken
model cannot be simply extrapolated to humans. No per-
manent deficiency of secretion of melatonin occurs in
patients with AIS. Evidence for a transient deficiency
before and/or during development of scoliosis is scant
and requires confirmation in a large number of subjects.
The diurnal variations in melatonin levels and the circa-
dian rhythm of secretion play an important role. There is
now evidence that melatonin may have a role in biologic
regulation of circadian rhythms, sleep, mood, and per-
haps reproduction, tumour growth, cardiovascular system
and aging. However, uncertainties and doubts still sur-
round the role of melatonin. It will be an important issue
of future research to investigate the role of melatonin in
human biology, the clinical efficacy and safety of mela-
tonin under different pathological situations.
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